Dean L. Schorno

2019 - Rigel Pharmaceuticals

In 2019, Dean L. Schorno earned a total compensation of $1M as Executive Vice President and Chief Financial Officer at Rigel Pharmaceuticals, a 13% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$191,580
Option Awards$420,682
Salary$412,000
Other$8,954
Total$1,033,216

Schorno received $420.7K in option awards, accounting for 41% of the total pay in 2019.

Schorno also received $191.6K in non-equity incentive plan, $412K in salary and $9K in other compensation.

Rankings

In 2019, Dean L. Schorno's compensation ranked 9,140th out of 13,971 executives tracked by ExecPay. In other words, Schorno earned more than 34.6% of executives.

ClassificationRankingPercentile
All
9,140
out of 13,971
35th
Division
Manufacturing
3,662
out of 5,695
36th
Major group
Chemicals And Allied Products
1,384
out of 2,194
37th
Industry group
Drugs
1,181
out of 1,880
37th
Industry
Pharmaceutical Preparations
875
out of 1,392
37th
Source: SEC filing on April 1, 2020.

Schorno's colleagues

We found six more compensation records of executives who worked with Dean L. Schorno at Rigel Pharmaceuticals in 2019.

2019

Raul Rodriguez

Rigel Pharmaceuticals

Chief Executive Officer

2019

Anne-Marie Duliege

Rigel Pharmaceuticals

Chief Medical Officer

2019

Dolly Vance

Rigel Pharmaceuticals

Executive Vice President, Corporate Affairs, General

2019

Eldon Mayer

Rigel Pharmaceuticals

Executive Vice President, Chief Commercial Officer

2019

Esteban Masuda

Rigel Pharmaceuticals

Executive Vice President, Research

2019

Wolfgang Dummer

Rigel Pharmaceuticals

Chief Medical Officer

News

You may also like